[A bivalent VP1 gene vaccine against Coxsackie virus B1/B3].
OBJECTIVE
To construct a bivalent VP1 gene vaccine against Coxsackie virus B1 and B3 (CVB1 and CVB3) and to test its immunogenicity in mice.


METHODS
The VP1 gene of CVB1 was amplified by RT-PCR. The VP1 genes of CVB1 and of CVB3 under the control of cytomegalovirus (CMV) promoter and SV40 promoter respectively were inserted oppositely into the pCR3-Uni, a eukaryotic expression vector. The resultant bivalent gene vaccine plasmid was used to inoculate 3-week-old BALB/c mice. Immunofluorescence test and RT-PCR were conducted 24, 48, and 96 hours after the transfection. Sera of the tested animals were sampled at 0, 2, 4, and 6 weeks after the inoculation and detected for CVB-specific antibodies by ELISA.


RESULTS
A bivalent gene vaccine plasmid of CVB1 and CVB3 was obtained. Samples of 4 and 6 weeks after the inoculation were shown to be CVB-antibody positive, while those of 0 and 2 weeks after the inoculation shown negative.


CONCLUSIONS
The gene vaccine thus constructed induces CVB-speicific antibodies in mice, and can serve as gene vaccine candidate for human beings.
Wu
X
X
The First Hospital of Harbin Medical University, Harbin 150001, China.
Zhao
T
T
Tian
Y
Y
D000818:Animals; D002213:Capsid / Q000235:genetics* / Q000276:immunology; D036022:Capsid Proteins; D002522:Chlorocebus aethiops; D003384:Coxsackievirus Infections / Q000517:prevention & control*; D004770:Enterovirus / Q000235:genetics / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D010957:Plasmids / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000276:immunology; D014709:Vero Cells; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics*
D036022:Capsid Proteins; D011993:Recombinant Fusion Proteins; D014765:Viral Vaccines